Literature DB >> 15338101

Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats.

B Pouzet1, M Paabøl Andersen, S Hogg.   

Abstract

RATIONALE: Schizophrenic patients have a deficit in prepulse inhibition (PPI) which can be modelled in rats by administration of direct or indirect dopamine (DA) receptor agonists and N-methyl-D-aspartate (NMDA) receptor antagonists. Moreover, antipsychotics reverse the disruptive effect of DA agonists and NMDA receptor antagonists in this rat model. Consequently, this model is considered as predictive of antipsychotic action in the clinic. However, the effect of compounds, such as antidepressants, used for other psychiatric disorders but also administered to patients with schizophrenia has not been well investigated in this model. Antidepressants have been suggested not to affect PPI in humans. Thus, antidepressants are not expected to antagonise PPI disruption in rats, and should normally be used as negative controls in this model.
OBJECTIVES: To investigate the effects of three antidepressant compounds, a serotonin reuptake inhibitor, a dopamine reuptake inhibitor, and a noradrenaline reuptake inhibitor in the rat PPI model.
METHODS: The effect of acute treatment with citalopram, bupropion and desipramine on d-amphetamine-disrupted and phencyclidine (PCP)-disrupted PPI in rats was investigated. Ziprasidone was tested as a positive control.
RESULTS: None of the antidepressants, in contrast to ziprasidone, reversed PCP-disrupted PPI in rats. Both desipramine and ziprasidone normalised d-amphetamine-disrupted PPI, while citalopram and bupropion were inactive.
CONCLUSIONS: PCP-disrupted PPI in rats was less sensitive to false positives than the d-amphetamine-disrupted PPI model, based on the antidepressants tested in this study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15338101     DOI: 10.1007/s00213-004-1976-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  40 in total

1.  Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication.

Authors:  V Kumari; W Soni; V M Mathew; T Sharma
Journal:  Arch Gen Psychiatry       Date:  2000-06

2.  Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia.

Authors:  B Pouzet; M Didriksen; J Arnt
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

3.  Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters.

Authors:  H Yu; R B Rothman; C M Dersch; J S Partilla; K C Rice
Journal:  Bioorg Med Chem       Date:  2000-12       Impact factor: 3.641

4.  Gating and habituation of the startle reflex in schizophrenic patients.

Authors:  D L Braff; C Grillon; M A Geyer
Journal:  Arch Gen Psychiatry       Date:  1992-03

5.  Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone.

Authors:  R S Mansbach; J Carver; S H Zorn
Journal:  Pharmacol Biochem Behav       Date:  2001 Jul-Aug       Impact factor: 3.533

6.  Evaluation of the efficacy of antipsychotic attenuation of phencyclidine-disrupted prepulse inhibition in rats.

Authors:  J L Wiley; K L Kennedy
Journal:  J Neural Transm (Vienna)       Date:  2002-04       Impact factor: 3.575

7.  The effects of some antidepressant drugs on prepulse inhibition of the acoustic startle (eyeblink) response and the N1/P2 auditory evoked response in man.

Authors:  M A Phillips; R W Langley; C M Bradshaw; E Szabadi
Journal:  J Psychopharmacol       Date:  2000-03       Impact factor: 4.153

8.  The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition.

Authors:  K Rasmussen; M R Gates; J E Burger; J F Czachura
Journal:  Neurosci Lett       Date:  1997-01-24       Impact factor: 3.046

9.  Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats.

Authors:  A Dekeyne; A Gobert; L Iob; L Cistarelli; C Melon; M J Millan
Journal:  Psychopharmacology (Berl)       Date:  2001-11       Impact factor: 4.530

10.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.

Authors:  R S Mansbach; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1989-12       Impact factor: 7.853

View more
  10 in total

1.  Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy.

Authors:  D Feifel; P D Shilling; G Melendez
Journal:  J Psychopharmacol       Date:  2010-11-24       Impact factor: 4.153

2.  Pharmacological stimulation of locus coeruleus reveals a new antipsychotic-responsive pathway for deficient sensorimotor gating.

Authors:  Karen M Alsene; Vaishali P Bakshi
Journal:  Neuropsychopharmacology       Date:  2011-04-20       Impact factor: 7.853

3.  The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.

Authors:  Kim Fejgin; Sergej Safonov; Erik Pålsson; Caroline Wass; Jörgen A Engel; Lennart Svensson; Daniel Klamer
Journal:  Psychopharmacology (Berl)       Date:  2007-01-19       Impact factor: 4.530

4.  Separable noradrenergic and dopaminergic regulation of prepulse inhibition in rats: implications for predictive validity and Tourette Syndrome.

Authors:  Neal R Swerdlow; Michele J Bongiovanni; Laura Tochen; Jody M Shoemaker
Journal:  Psychopharmacology (Berl)       Date:  2006-04-01       Impact factor: 4.530

5.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

Authors:  Tatiana Lipina; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2009-12-16       Impact factor: 4.530

6.  Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice.

Authors:  Nancy A Shanahan; Kerri A Holick Pierz; Virginia L Masten; Christian Waeber; Mark Ansorge; Jay A Gingrich; Mark A Geyer; Rene Hen; Stephanie C Dulawa
Journal:  Biol Psychiatry       Date:  2008-11-14       Impact factor: 13.382

7.  Effects of experimental acute tryptophan depletion on acoustic startle response in females.

Authors:  Christine Norra; Stefanie Becker; Sabine C Herpertz; Hanns Jürgen Kunert
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-09-27       Impact factor: 5.270

Review 8.  Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.

Authors:  A de Bartolomeis; E F Buonaguro; F Iasevoli
Journal:  Psychopharmacology (Berl)       Date:  2012-11-21       Impact factor: 4.530

9.  T-817MA, a novel neurotrophic compound, ameliorates phencyclidine-induced disruption of sensorimotor gating.

Authors:  Tomonori Seo; Tomiki Sumiyoshi; Masahiko Tsunoda; Kodai Tanaka; Takashi Uehara; Tadasu Matsuoka; Hiroko Itoh; Masayoshi Kurachi
Journal:  Psychopharmacology (Berl)       Date:  2008-02-05       Impact factor: 4.530

10.  Influence of clozapine on neurodevelopmental protein expression and behavioral patterns in animal model of psychiatric disorder induced by low-level of lead.

Authors:  Hwayoung Lee; Minyoung Lee; Hyung-Ki Kim; Young Ock Kim; Jun-Tack Kwon; Hak-Jae Kim
Journal:  Korean J Physiol Pharmacol       Date:  2019-10-24       Impact factor: 2.016

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.